Letermovir prophylaxis may increase the risk of graft-versus-host disease after haploidentical hematopoietic stem cell transplantation with αβ+ T cell depleted grafts.

Prevymis (letermovir) - Merck (MSD)

Letermovir prophylaxis may increase the risk of graft-versus-host disease after haploidentical hematopoietic stem cell transplantation with αβ+ T cell depleted grafts. (PubMed, Bone Marrow Transplant) - Jun 11, 2025 - No abstract available
Journal • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Transplantation

http://www.ncbi.nlm.nih.gov/pubmed/40494916

Beata Tomaszewska-Toporska; Dominik Turkiewicz; Evelina Elmér; Josefina Dykes; Robert Palmason; Stig Lenhoff; Stina Wichert

Jun 11, 2025